Polyphor launches the development of an inhaled antibiotic murepavadin
Polyphor Ltd has announced €5m funding, in order to support and accelerate the development of an inhaled dosage form of murepavadin...
List view / Grid view
Polyphor Ltd has announced €5m funding, in order to support and accelerate the development of an inhaled dosage form of murepavadin...
NPL's new approach informed by government priorities, consultancy with industry and the NHS, and a century of expertise, will see it focus on some of the world’s biggest health challenges, from supporting the diagnosis and treatment of cancer and dementia, to reducing attrition rates in drug development, to creating new…
Researchers have found that a novel combination of antibiotics that was able to kill E. coli carrying mcr-1 and ndm-5 genes within 24 hours...
Nanoengineers have developed micromotors to treat a bacterial infection in the stomach...
GlobalData latest report states that the major drivers of this growth include the projected launch of prophylactic options for the prevention of Clostridium difficile infections...
A new antibiotic, produced by bacteria found on a species of African ant, is very potent against antibiotic-resistant ‘superbugs’ like MRSA according to scientists.
22 May 2017 | By Niamh Marriott, Junior Editor
Approximately one in four adults prescribed an antibiotic in an outpatient setting for community-acquired pneumonia does not respond to treatment...
ResistancePlus™ MG Test would bring disease and antibiotic resistance testing for potential “superbug”...
27 April 2017 | By Niamh Marriott, Junior Editor
Polyphor presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA)...
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Antibiotics - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of antibiotics.
20 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The recent $55M Series C financing will allow MicuRx to complete this Phase 3 study, and at a vital time with antibiotic resistance at an all time high...
15 September 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Following an article about the worrying presence of E.coli in UK supermarkets, our sister title New Food caught up with Emma Rose from Alliance to Save Our Antibiotics for an exclusive interview discussing the latest issues facing antibiotic resistance…
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two…
In this issue: Biosimilars, Regulation, Packaging, Microfluidics, Microbiology, PAT, Antibiotic Resistance, and much more...